The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized, open label, multicenter, phase II trial of transcatheter arterial chemoembolization (TACE) therapy in combination with sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
 
Masatoshi Kudo
Honoraria - Abbvie; Bayer; Bristol-Myers Squibb Japan; EA Pharma; Eisai; Gilead Sciences; Merck Serono; Merck Serono; MSD; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; MSD
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Kazuomi Ueshima
Honoraria - Bayer
Consulting or Advisory Role - Eisai
 
Takuji Torimura
No Relationships to Disclose
 
Nobukazu Tanabe
No Relationships to Disclose
 
Masafumi Ikeda
Honoraria - Abbott Japan; Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Dainippon Sumitomo Pharma; Eisai; Lilly Japan; Nobelpharma; Novartis; Otsuka; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Bristol-Myers Squibb Japan; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; MSD; NanoCarrier; Novartis; Shire; Teijin Pharma
Research Funding - ASLAN Pharmaceuticals; AstraZeneca; Baxalta/Shire; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Eisai; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; NanoCarrier; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takara Bio; Yakult Pharmaceutical; Zeria Pharmaceutical
 
Hiroshi Aikata
No Relationships to Disclose
 
Namiki Izumi
Speakers' Bureau - Abbvie; Bayer Yakuhin; Gilead Sciences; Otsuka
 
Takahiro Yamasaki
No Relationships to Disclose
 
Shunsuke Nojiri
No Relationships to Disclose
 
Keisuke Hino
No Relationships to Disclose
 
Hidetaka Tsumura
No Relationships to Disclose
 
Norio Isoda
Research Funding - Abbvie
 
Kohichiroh Yasui
No Relationships to Disclose
 
Teiji Kuzuya
No Relationships to Disclose
 
Takuji Okusaka
Honoraria - AstraZeneca; Baxter; Bayer Yakuhin; Bristol-Myers Squibb; Celgene; Chugai Pharma; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Fujifilm; Lilly; LtdPharma; Merck Serono; Nippon Chemiphar; Nippon Kayaku; Nobelpharma; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - Daiichi Sankyo; Dainippon Sumitomo Pharma; Lilly; Nippon Boehringer Ingelheim; Taiho Pharmaceutical; Zeria Pharmaceutical
Research Funding - AstraZeneca; Baxter; Bayer Yakuhin; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Kowa; Kyowa Hakko Kirin; Lilly; Merck Serono; NanoCarrier; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Junji Furuse
Honoraria - Astellas Pharma; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Sawai Pharmaceutical Co; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Asahi Kasei; Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; Fujifilm; J-Pharma; Kyowa Hakko Kirin; MSD; Novartis; Ono Pharmaceutical; Otsuka; Sandoz; Sanofi; Sawai Pharmaceutical Co; Shionogi; Shire; Sumitomo Dainippon; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
Speakers' Bureau - Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst); Zeria Pharmaceutical (Inst)
 
Norihiro Kokudo
No Relationships to Disclose
 
Kiwamu Okita
No Relationships to Disclose
 
Kenichi Yoshimura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Eisai; Lilly; Taiho Pharmaceutical; Takeda
 
Yasuaki Arai
No Relationships to Disclose